116 related articles for article (PubMed ID: 20953941)
1. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
[TBL] [Abstract][Full Text] [Related]
2. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
[TBL] [Abstract][Full Text] [Related]
4. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
[TBL] [Abstract][Full Text] [Related]
5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
6. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
[TBL] [Abstract][Full Text] [Related]
7. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
[TBL] [Abstract][Full Text] [Related]
8. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
9. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
10. [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface].
Wang Q; Lu Y; Li S; Wang M; Cai J
Sheng Wu Gong Cheng Xue Bao; 2011 Jan; 27(1):131-6. PubMed ID: 21553499
[TBL] [Abstract][Full Text] [Related]
11. Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y
J Immunol Methods; 2016 Sep; 436():41-9. PubMed ID: 27374866
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.
Semac I; Palomba C; Kulangara K; Klages N; van Echten-Deckert G; Borisch B; Hoessli DC
Cancer Res; 2003 Jan; 63(2):534-40. PubMed ID: 12543813
[TBL] [Abstract][Full Text] [Related]
14. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
15. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
Takei K; Yamazaki T; Sawada U; Ishizuka H; Aizawa S
Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
18. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
19. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
